Breast Cancer | Specialty

Atezolizumab Plus Chemo Significantly Improves pCR Rates in Early TNBC, Irrespective of PD-L1 Status

September 20th 2020

The addition of neoadjuvant atezolizumab to nab-paclitaxel plus doxorubicin and cyclophosphamide significantly improved pathologic complete responses in patients with stage 2 or stage 3 triple-negative breast cancer, compared with placebo plus chemotherapy.

Abemaciclib/Tamoxifen Shows OS Benefit in HR+, HER2- Metastatic Breast Cancer

September 20th 2020

The addition of tamoxifen to abemaciclib resulted in an improvement in overall survival compared with abemaciclib monotherapy in in patients with hormone receptor–positive, HER2-negative metastatic breast cancer, with benefit observed across all patient subgroups.

Sacituzumab Govitecan Significantly Improves Survival in Metastatic TNBC

September 19th 2020

Treatment with sacituzumab govitecan led to a 59% reduction in the risk of disease progression or death compared with physician’s choice of single-agent chemotherapy in patients with previously treated metastatic triple-negative breast cancer.

SOLAR-1 OS Data Suggests Benefit in HR+/HER2– PIK3CA-Mutant Breast Cancer Subgroups

September 19th 2020

Although the SOLAR-1 trial did not cross the prespecified O’Brien-Fleming efficacy boundary in postmenopausal patients with PIK3CA-mutant, hormone receptor–positive, HER2-negative advanced breast cancer, alpelisib and fulvestrant nevertheless prolonged the median OS.

PD-L1 Status Guides TIL activity in NeoTRIPaPDL1

September 19th 2020

Although atezolizumab did not improve pathological complete response when added to carboplatin and nab-paclitaxel, the immunotherapy increased the pCR by 10% or more in “immune-rich” groups with high-risk and locally advanced triple-negative breast cancer, and also turned PD-L1 negative tumors positive in most immunotherapy-treated patients.

Ipatasertib/Chemotherapy Combo Falls Flat in HR+ HER2- Advanced Breast Cancer

September 18th 2020

The addition of ipatasertib to paclitaxel failed to improve progression-free survival and objective response rates versus placebo plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered hormone receptor–positive, HER2-negative advanced breast cancer.

New Options Mark Major Strides in Treating HER2+ Metastatic Breast Cancer

September 16th 2020

A panel of breast cancer experts discuss a variety of new and emerging agents to treat patients with advanced or metastatic HER2-positive breast cancer with disease progression following treatment with at least 1 anti-HER2 therapy.

Precision Medicine in Metastatic Triple Negative Breast Cancer

September 16th 2020

HER2+ Early-Stage Breast Cancer: Peri-Operative Therapy

September 16th 2020

Metastatic HER2+ Breast Cancer

September 16th 2020

Metastatic HR+ Breast Cancer

September 16th 2020

Dr. Han on the APHINITY Trial in HER2+ Early-Stage Breast Cancer

September 11th 2020

Heather ​S. Han, MD, discusses the benefit of adding pertuzumab to trastuzumab and chemotherapy in the phase 3 APHINITY trial in patients with HER2-positive early-stage breast cancer.

Tolaney Talks Tailored Treatment Strategies in HER2+ Breast Cancer

September 10th 2020

In our exclusive interview, Sara M. Tolaney, MD, MPH, shares insight on how risk status is being used to tailor HER2-directed therapies to patients with early-stage HER2-positive breast cancer, key trials focused on delineating optimal deescalated and escalated treatment strategies, and ongoing research in the HER2-low setting.

Dr. Burris on Recent Advances in TNBC

September 8th 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses recent advancements made in the field of triple-negative breast cancer.

Dr. Hamilton on the Complex Treatment Algorithm for HER2+ Breast Cancer

September 8th 2020

Erika P. Hamilton, MD, discusses the complex treatment algorithm for HER2-positive breast cancer.

Daiichi Sankyo, Gustave Roussy Research Partnership Holds Promise for NSCLC, Breast Cancer Paradigms

September 8th 2020

A multi-year, multi-study research collaboration between Daiichi Sankyo and Gustave Roussy Cancer Center will support the clinical, translational, and preclinical evaluation of 2 of the company’s lead antibody-drug conjugates: DS-1062 in advanced non–small cell lung cancer, and patritumab deruxtecan in metastatic breast cancer.

FDA Issues Alert Regarding Efficacy and Safety of Atezolizumab/Paclitaxel in Breast Cancer

September 8th 2020

The FDA has issued an alert that the phase 3 IMpassion131 trial failed to show the effectiveness of atezolizumab plus paclitaxel in treatment-naïve patients with inoperable locally advanced or metastatic triple-negative breast cancer.

Breast Cancer–Specific Survival Worse Among Survivors of Childhood or Young Adult Primary Cancer Treated With Radiotherapy

September 8th 2020

Premenopausal women with breast cancer who were previously treated with radiotherapy for a primary childhood, adolescent, or young adult cancer were found to have worse breast cancer–specific survival.

New Era for Targeting HER2 Beckons in Breast Cancer and Beyond

September 3rd 2020

Precision medicine advancements are opening a new chapter in the development of anticancer therapies that target the HER2 pathway, resulting in 3 approvals for breast cancer in less than a year and raising hopes for attacking other cancer types.

Dr. Ahmed on the Impact of Neratinib on CNS Metastases in HER2+ Breast Cancer

September 3rd 2020

Kamran A. Ahmed, MD, discusses the impact of neratinib on patients with central nervous system metastases and HER2-positive breast cancer.